Stryker wins FDA nod for cementless Mako total knee system

Stryker (NYSE:SYK) said today it won FDA 510(k) clearance for its cementless Mako total knee system with Triathlon Tritanium. The Kalamazoo, Mich.-based company touted the Triathlon Titanium as combining kinematics from its Triathlon knee with highly porous biologic fixation technology. The system features the company’s Tritanium tibial baseplate and metal-backed patella components as well, the company said. Stryker said that cementless procedures are increasing in popularity, and the newly cleared platform expands the robotics offerings for orthopedic surgeons seeking an alternative to bone cement. “With the rise in demand for cementless knee technology, we believe this new offering can have a positive impact on procedural efficiency and patient outcomes. We’re excited to continue to lead in robotic technology and combine two of our most advanced and differentiated products to provide surgeons with the ability to transform orthopaedic surgery,” Stryker joint replacement division prez Stuart Simpson said in a press release. Late last week, Stryker won a $3.4 million tax-rebate incentive from the state of Utah to expand its neurotechnology training and manufacturing center in Salt Lake City, according to a Salt Lake Tribune report. See the best minds in medtech live at DeviceTalks West, Dec. 11–12 in Orange County, Calif. The post Stryker wins FDA nod for cementless Mako total knee system appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: 510(k) Food & Drug Administration (FDA) Orthopedics Regulatory/Compliance Stryker Source Type: news